A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 7, 2005, Pages 647-655

  Weiss, Margaret ^c   Tannock, Rosemary ^b   Kratochvil, Christopher ^d   Dunn, David ^e   Velez Borras, Jesus ^f   Thomason, Christine ^a   Tamura, Roy ^a   Kelsey, Douglas ^a   Stevens, Linda ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^e INDIANA UNIVERSITY   (United States)

^f University Hospital   (Puerto Rico)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Nonstimulants; School

Indexed keywords

ATOMOXETINE; PLACEBO;

ABDOMINAL PAIN; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EMOTIONAL DISORDER; FEMALE; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCHOOL HEALTH SERVICE; SCORING SYSTEM; SIDE EFFECT; SYMPTOMATOLOGY; TREATMENT OUTCOME; VOMITING;

EID: 21044444747     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000163280.47221.c9     Document Type: Article

References (25)

1. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). Washington, DC: American Psychiatric Association
2. American Psychiatric Association (2000), Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association
3. Brown TE (2001), Brown Attention-Deficit Disorder Scales for Children and Adolescents. San Antonio, TX: The Psychological Corporation
4. Brown WJ, Biederman J, Spencer T et al. (2002), Efficacy and safety of atomoxetine in the treatment of attention deficit/hyperactivity disorder in children and adolescents. Eur Neuropsychopharmacol 12 (suppl 3):S411
5. Conners CK (1997), Conners Rating Scales: Revised Technical Manual. North Tonawanda, NY: Multi-Health Systems
6. Conners CK (2002), Forty years of methylphenidate treatment in attention-deficit/hyperactivity disorder. J Atten Disord 6 (suppl 1):S17-S30
7. DuPaul GJ, Rapport MD, Perriello LM (1991), Teacher rating scales of academic skills: the development of the academic performance rating scale. School Psychol Rev 20:284-300
8. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R (1998), ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York: Guilford
9. Faries DE, Yalcin I, Harder D, Heiligenstein JH (2001), Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:39-47
10. Gresham FM, Elliott SN (1990), Social Skills Rating System Manual. Circle Pines, MN: American Guidance Service
11. Guy W (1976), ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare
12. Heiligenstein JH, Spencer TJ, Faries DE, Biederman J, Kratochvil C, Conners CK (2000), Efficacy of atomoxetine vs. placebo in pediatric outpatients with ADHD. Presented at The 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, New York, October 24-29
13. Hughes CW, Preskorn SH, Weller E, Weller R, Hassanein R, Tucker S (1990), The effect of concomitant disorders in childhood depression on predicting treatment response. Psychopharmacol Bull 26:235-238
14. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N (1996), Kiddie-SADS-Present and Lifetime Version (K-SADS-PL). Pittsburgh: University of Pittsburgh Press
15. Kratochvil CJ, Wernicke J, Schuh K, Zhang S, Faries D, Kelsey D (2002), Long-term safety of atomoxetine in children treated for ADHD. Presented at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 22-27
16. Michelson D, Allen AJ, Busner J et al. (2002), Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 159: 1896-1901
17. Michelson D, Faries D, Wernicke J et al. (2001), Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactiviry disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 108:e83
18. MTA Cooperative Group (1999), A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56:1073-1086
19. Murphy K, Barkley RA (1996), Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Atten Disord 1:147-161
20. Newcorn J (2002), Efficacy trials of atomoxetine for ADHD in children, adolescents and adults. Presented at the 49th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, San Francisco, October 22-27
21. Newcorn JH, Allen AJ, Sutton V et al. (2003), Characteristics of placebo responders and remitters in pediatric ADHD clinical trials. Presented at the 50th Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Miami, October 14-19
22. Schachar R, Ickowicz A (1999), Pharmacological treatment of ADHD. In: Handbook of Disruptive Behavior Disorders, Quay HC, Hogan AE, eds. New York: Kluwer Academic/Plenum Publishers, pp 221-254
23. Senn SJ (1997), Statistical Issues in Drug Development. Chichester: Wiley
24. Spencer T, Heiligenstein JH, Biederman J et al. (2002), Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 63:1140-1147
25. Tannock R, Hum M, Masellis M, Humphries T, Schachar R (2002), Teacher Telephone Interview for Children's Academic Performance, Attention, Behavior, and Learning: DSM-IV Version (TTI-IV). Toronto: The Hospital for Sick Children